Common name
N-methylbutan-1-amine
IUPAC name
N-methylbutan-1-amine
SMILES
N(CCCC)C
Common name
N-methylbutan-1-amine
IUPAC name
N-methylbutan-1-amine
SMILES
N(CCCC)C
INCHI
InChI=1S/C5H13N/c1-3-4-5-6-2/h6H,3-5H2,1-2H3
FORMULA
C5H13N
Common name
N-methylbutan-1-amine
IUPAC name
N-methylbutan-1-amine
Molecular weight
87.163
clogP
0.682
clogS
-1.817
Frequency
0.0034
HBond Acceptor
0
HBond Donor
1
Total PolarSurface Area
12.03
Number of Rings
0
Rotatable Bond
3
| Drug ID | Common name | Structure CAS | Compound class | Therapeutic area |
|---|---|---|---|---|
| FDBD00019 | Spermine |
|
Dietary Supplements; Micronutrients; Supplements; | For nutritional supplementation, also for treating dietary shortage or imbalance. |
| FDBD00195 | Ibutilide |
|
Anti-Arrhythmia Agents; Cardiovascular System; Antiarrhythmics, Class III; Antiarrhythmics, Class I and Iii; Cardiac Therapy; Antiarrythmics, Class I and Iii; | Indicated for the rapid conversion of atrial fibrillation or atrial flutter of recent onset to sinus rhythm. |
| FDBD00793 | Salmeterol |
|
Sympathomimetics; Adrenergic beta-2 Receptor Agonists; Bronchodilator Agents; Respiratory System; Drugs for Obstructive Airway Diseases; Selective Beta-2-Adrenoreceptor Agonists; Adrenergics, Inhalants; Cytochrome P-450 CYP2C8 Inhibitors; Cytochrome P-450 CYP2C8 Inducers; CYP3A4 Inhibitors; Beta2 Agonists; | For the treatment of asthma and chronic obstructive pulmonary disease (COPD). |
| FDBD00952 | Arbutamine |
|
Cardiovascular System; Cardiac Therapy; Adrenergic and Dopaminergic Agents; Cardiac Stimulants Excl. Cardiac Glycosides; Beta2 Agonists; | Used to elicit acute cardiovascular responses (cardiac stumulant), similar to those produced by exercise, in order to aid in diagnosing the presence or absence of coronary artery disease (CAD) in patients who cannot exercise adequately. |
| FDBD01064 | Halofantrine |
|
Antimalarials; Antiprotozoal Agents; Antiparasitic Products, Insecticides and Repellents; Cytochrome P-450 CYP2C8 Inhibitors; Cytochrome P-450 CYP2C8 Inducers; CYP2D6 Inducers; CYP2D6 Inducers (strong); CYP3A4 Inhibitors; | For treatment of Severe malaria. |
| FDBD01127 | Fosamprenavir |
|
Anti-HIV Agents; Protease Inhibitors; HIV Protease Inhibitors; Prodrugs; Antiinfectives for Systemic Use; Direct Acting Antivirals; Antivirals for Systemic Use; CYP3A4 Inhibitors; | Indicated in combination with other antiretroviral agents for the treatment of human immunodeficiency virus (HIV-1) infection, as well as postexposure prophylaxis of HIV infection in individuals who have had occupational or nonoccupational exposure to potentially infectious body fluids of a person known to be infected with HIV when that exposure represents a substantial risk for HIV transmission. The use of fosamprenavir is pending revision due to a potential association between the drug and myocardial infarction and dyslipidemia in HIV infected adults. |
| FDBD01333 | Dronedarone |
|
Anti-Arrhythmia Agents; Adrenergic alpha-1 Receptor Antagonists; Cardiovascular System; Antiarrhythmics, Class III; Antiarrhythmics, Class I and Iii; Cardiac Therapy; Antiarrythmics, Class I and Iii; CYP2D6 Inducers; CYP2D6 Inducers (strong); CYP3A4 Inhibitors; Combined Inhibitors of CYP3A4 and P-glycoprotein; | Management of paroxysmal or persistent atrial fibrillation via restoration of normal sinus rhythm. |
| FDBD01448 | Lumefantrine |
|
Antimalarials; Antiprotozoal Agents; Antiparasitic Products, Insecticides and Repellents; CYP2D6 Inducers; CYP2D6 Inducers (strong); CYP3A4 Inhibitors; | Lumefantrine and artemether combination therapy is indicated for the treatment of acute uncomplicated malaria caused by . |
| FDBD01592 | Hexoprenaline |
|
Adrenergic beta-2 Receptor Agonists; Bronchodilator Agents; Tocolytic Agents; Respiratory System; Drugs for Obstructive Airway Diseases; Selective Beta-2-Adrenoreceptor Agonists; Adrenergics, Inhalants; Adrenergics for Systemic Use; | |
| FDBD02895 | dodicin |
|
Fungicide | Fungicide |
10 ,
2
| FRAGNAME | PDBID | SIMILIRITY | XSCORE | SMILE | HAC |
|---|---|---|---|---|---|
| 1p0y_ligand_3_3.mol2 | 1p0y | 1 | -6.17 | C([NH2+]C)CCC | 6 |
| 1w6j_ligand_5_786.mol2 | 1w6j | 1 | -6.10 | C(C[NH+](C)C)CC | 7 |
| 1vsn_ligand_3_111.mol2 | 1vsn | 1 | -6.09 | C(CC(C)C)[NH2+]C | 7 |
| 1h3b_ligand_5_210.mol2 | 1h3b | 1 | -6.08 | C(CC)C[NH+](C)C | 7 |
| 2p1c_ligand_5_77.mol2 | 2p1c | 1 | -6.07 | CCCC[NH+](C)C | 7 |
| 4zun_ligand_4_30.mol2 | 4zun | 1 | -6.07 | [NH2+](C)CCCC | 6 |
| 1gsz_ligand_5_786.mol2 | 1gsz | 1 | -6.04 | C[NH+](C)CCCC | 7 |
| 1w6j_ligand_4_480.mol2 | 1w6j | 1 | -6.04 | C(C[NH2+]C)CC | 6 |
| 1o6r_ligand_5_210.mol2 | 1o6r | 1 | -6.03 | C(CC)C[NH+](C)C | 7 |
163 ,
17
